Lund University Cancer Center Distinguished Seminar

23 apr '18
13:30 - 15:00
Auditorium, Medicon Village, Scheelevägen 2, Lund
Lund University Cancer Center and Medicon Village

“From monocyte re-programming to the expansion of Tumor Infiltrating Lymphocytes (TILs) for Adoptive Cell Therapy in human breast cancer”

Marie-Agnès Doucey, Ludwig Institute for Cancer Research, University of Lausanne, CH1066 Epalinges, Switzerland.

Time and location: April 23rd at 13.30, MV Lecture Hall (Hörsalen), coffee and cake at 14.30

Marie-Agnès Doucey is a project leader at the Ludwig Institute for Cancer Research (Lausanne Branch, Switzerland) and a faculty member (MER) at the University of Lausanne. She was educated as both a biologist and a biotechnological engineer (Strasbourg, France) and holds a Ph.D. in Biochemistry (Friedrich-Miescher Institute, Basel, Switzerland) as well as master degrees in molecular biology and in plant physiology (University de Bourgogne and University Louis Pasteur, France).

In 2004, she began working as a project leader in Lausanne University Hospital where she hired her first research group. Her research expertise focused primarily on human memory T cells before she began leading an interdisciplinary program combining experimental oncology, Boolean system modeling and nano-biosensors to predict the behavior of pro-tumoral monocytes in breast cancer. In January 2013, Dr. Coukos (Director of the Ludwig Institute for Cancer Research, Lausanne Branch, and Head of the Department of Oncology, Lausanne University Hospital) invited her to lead the systems immunopharmacology line of work in his newly established laboratory.

Her primary research interest is to understand and reverse the complex molecular mechanisms of immune cell dysfunction within the tumor microenvironment in order to develop novel immunotherapeutic interventions for cancer patients. She contributed to more than 45 scientific publications and is the primary inventor of a patent on the first reported intervention on the tumor microenvironment to rescue and reverse dysfunctional cancer-specific tumor infiltrating lymphocytes for use in the personalized treatment of patients with breast cancer.
Selected publications:

  1. Turrini R, Pabois A, Coukos G, Xenarios I, Delaloye J-F, Doucey M.-A. TIE-2 expressing monocytes in human cancer. Review. Oncoimmunology, 2017, 16;6(4):e1303585.
  2. Crespo I, Götz L, Lietchi R, Doucey M-A, Xenarios I.Identification of combinations of marker genes for favorable prognosis in cancer by non-hypothesis-driven iterative survival analysis. Npg, Systems Biology and Applications, 2016, 2:16037.
  3. Crespo I, Doucey M-A, Xenarios I. Social networks help to infer causality in the tumor microenvironment. 2016, BMC research note, 15;9:168/s13104-016-1976-8.
  4. Puppo F, Doucey M.-A, Delaloye J.-F, Moh Y, Pandraud G, Sarro M, DeMicheli G and Carrara S. SiNW-FET in-Air Biosensors for High Sensitive and Specific Detection in Breast Tumor Extract. IEEE Sensors Journal. 2016, Volume 16, Issue 10, pp. 3374-3381.
  5. N Guex, I Crespo, I Xenarios, S Bron, A Ifticene-Treboux, E Faes-van’t Hull, S Kharoubi, R Liechti, P Werffeli, M Ibberson, F Majo, M Nicolas, J Laurent, A Garg, K Zaman, Hans-Anton Lehr, B Stevenson, C Rüegg, G. Coukos, J-F Delaloye and M.-A. Doucey. Systems modeling approach predicts the phenotypic reversal of breast tumor pro-angiogenic TIE-2 expressing monocytes (TEM). Plos. Comp. Biol. 2015, Mar 13;11(3):e1004050.


Kristina Lundberg, Dep of. Immunotechnology,